Skip to main content
. 2022 Mar 2;2022(3):CD002795. doi: 10.1002/14651858.CD002795.pub3

Comparison 18. Total effect of medication versus placebo.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
18.1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar) scale: no. of responders 19 1822 Risk Ratio (M‐H, Random, 95% CI) 0.74 [0.64, 0.85]
18.1.1 Anticonvulsants 4 315 Risk Ratio (M‐H, Random, 95% CI) 0.87 [0.63, 1.21]
18.1.2 Antipsychotics 2 43 Risk Ratio (M‐H, Random, 95% CI) 0.51 [0.16, 1.67]
18.1.3 MAOIs 2 178 Risk Ratio (M‐H, Random, 95% CI) 0.80 [0.44, 1.44]
18.1.4 GR205171 1 39 Risk Ratio (M‐H, Random, 95% CI) 0.78 [0.42, 1.44]
18.1.5 GSK561679 1 128 Risk Ratio (M‐H, Random, 95% CI) 1.08 [0.88, 1.31]
18.1.6 SSRIs 8 1078 Risk Ratio (M‐H, Random, 95% CI) 0.66 [0.59, 0.74]
18.1.7 TCAs 1 41 Risk Ratio (M‐H, Random, 95% CI) 0.59 [0.37, 0.94]
18.2 Drop‐out rate due to treatment emergent adverse effects 37 4212 Risk Ratio (M‐H, Random, 95% CI) 0.98 [0.96, 1.00]
18.2.1 Alpha‐blockers 1 304 Risk Ratio (M‐H, Random, 95% CI) 0.99 [0.91, 1.08]
18.2.2 Anticonvulsants 5 348 Risk Ratio (M‐H, Random, 95% CI) 0.98 [0.92, 1.05]
18.2.3 Antipsychotics 5 174 Risk Ratio (M‐H, Random, 95% CI) 0.94 [0.85, 1.03]
18.2.4 Benzodiazepines 1 32 Risk Ratio (M‐H, Random, 95% CI) 1.00 [0.89, 1.12]
18.2.5 Dopamine beta‐hydroxylase inhibitors 1 91 Risk Ratio (M‐H, Random, 95% CI) 0.88 [0.54, 1.41]
18.2.6 Ganaxolone 1 112 Risk Ratio (M‐H, Random, 95% CI) 1.02 [0.94, 1.11]
18.2.7 GR205171 1 39 Risk Ratio (M‐H, Random, 95% CI) 1.00 [0.91, 1.10]
18.2.8 MAOIs 2 159 Risk Ratio (M‐H, Random, 95% CI) 0.97 [0.91, 1.04]
18.2.9 NaSSAs 1 36 Risk Ratio (M‐H, Random, 95% CI) 0.87 [0.68, 1.11]
18.2.10 SARIs 1 42 Risk Ratio (M‐H, Random, 95% CI) 0.87 [0.70, 1.09]
18.2.11 SNRIs 2 687 Risk Ratio (M‐H, Random, 95% CI) 0.98 [0.88, 1.10]
18.2.12 SSRIs 13 2047 Risk Ratio (M‐H, Random, 95% CI) 0.98 [0.96, 1.00]
18.2.13 TCAs 3 141 Risk Ratio (M‐H, Random, 95% CI) 0.92 [0.81, 1.05]
18.3 Clinically Administered PTSD Scale (CAPS): CAPS Total 34 4639 Mean Difference (IV, Random, 95% CI) ‐4.79 [‐6.64, ‐2.94]
18.3.1 Alpha‐blockers 1 271 Mean Difference (IV, Random, 95% CI) 0.10 [‐5.13, 5.33]
18.3.2 Anticonvulsants 5 411 Mean Difference (IV, Random, 95% CI) ‐0.35 [‐6.54, 5.84]
18.3.3 Antipsychotics 3 129 Mean Difference (IV, Random, 95% CI) ‐14.10 [‐22.57, ‐5.62]
18.3.4 Dopamine beta‐hydroxylase inhibitors 1 86 Mean Difference (IV, Random, 95% CI) ‐5.27 [‐16.72, 6.18]
18.3.5 Ganaxolone 1 99 Mean Difference (IV, Random, 95% CI) ‐2.50 [‐10.92, 5.92]
18.3.6 GR205171 1 39 Mean Difference (IV, Random, 95% CI) ‐7.60 [‐22.59, 7.39]
18.3.7 Hypnotics 1 16 Mean Difference (IV, Random, 95% CI) ‐1.00 [‐19.57, 17.57]
18.3.8 MAOIs 2 178 Mean Difference (IV, Random, 95% CI) ‐5.06 [‐15.93, 5.81]
18.3.9 NaSSAs 2 419 Mean Difference (IV, Random, 95% CI) ‐4.38 [‐10.32, 1.56]
18.3.10 SARIs 1 41 Mean Difference (IV, Random, 95% CI) ‐5.60 [‐21.26, 10.06]
18.3.11 SNRIs 2 687 Mean Difference (IV, Random, 95% CI) ‐8.11 [‐12.29, ‐3.92]
18.3.12 SSRIs 14 2263 Mean Difference (IV, Random, 95% CI) ‐4.84 [‐7.64, ‐2.05]
18.4 Drop‐out rate due to any cause 48 5302 Risk Ratio (M‐H, Random, 95% CI) 0.95 [0.90, 1.01]
18.4.1 Alpha‐blockers 1 303 Risk Ratio (M‐H, Random, 95% CI) 0.99 [0.89, 1.11]
18.4.2 Anticonvulsants 7 447 Risk Ratio (M‐H, Random, 95% CI) 1.02 [0.90, 1.16]
18.4.3 Antipsychotics 4 133 Risk Ratio (M‐H, Random, 95% CI) 1.25 [0.93, 1.66]
18.4.4 Benzodiazepines 1 16 Risk Ratio (M‐H, Random, 95% CI) 0.86 [0.39, 1.89]
18.4.5 Dopamine beta‐hydroxylase inhibitors 1 100 Risk Ratio (M‐H, Random, 95% CI) 0.92 [0.75, 1.12]
18.4.6 Ganaxolone 1 105 Risk Ratio (M‐H, Random, 95% CI) 0.81 [0.65, 1.02]
18.4.7 GR205171 1 47 Risk Ratio (M‐H, Random, 95% CI) 1.57 [1.03, 2.41]
18.4.8 Hypnotics 1 25 Risk Ratio (M‐H, Random, 95% CI) 0.72 [0.39, 1.31]
18.4.9 MAOIs 1 64 Risk Ratio (M‐H, Random, 95% CI) 0.98 [0.71, 1.35]
18.4.10 NaSSAs 3 200 Risk Ratio (M‐H, Random, 95% CI) 0.99 [0.88, 1.12]
18.4.11 NK‐1 receptor antagonists 1 129 Risk Ratio (M‐H, Random, 95% CI) 0.58 [0.32, 1.04]
18.4.12 SARIs 2 101 Risk Ratio (M‐H, Random, 95% CI) 0.81 [0.68, 0.97]
18.4.13 SNRIs 1 329 Risk Ratio (M‐H, Random, 95% CI) 1.04 [0.90, 1.21]
18.4.14 SSRIs 21 3206 Risk Ratio (M‐H, Random, 95% CI) 0.94 [0.87, 1.03]
18.4.15 TCAs 2 97 Risk Ratio (M‐H, Random, 95% CI) 0.79 [0.62, 0.99]